Table 2.

Mutational status of six human thyroid cancer cell lines derived from three types of thyroid carcinomas.

Cell lines	BRAF	NRAS	HRAS	KRAS	PI3KCA	PTEN	TP53	RET/PTC1	RET/PTC3	PAX8/PPARγ
WRO (FTC)	GTG-> GAG V600E*	wt	wt	wt	wt	wt	wt	−	−	−
FTC133 (FTC)	wt	wt	wt	wt	wt	CGA->TGA R130STOP	CGT->CAT R273H	−	−	−
B-CPAP (PTC)	GTG-> GAG V600E	wt	wt	wt	wt	wt	GAC->TAC D259Y	−	−	−
TPC1 (PTC)	wt	wt	wt	wt	wt	wt	wt	+	−	−
K1 (PTC)	GTG-> GAG V600E*	wt	wt	wt	GAA->AAA E542K*	wt	CGA->CGC R213R	−	−	−
8505c (ATC)	GTG-> GAG V600E	wt	wt	wt	wt	wt	CGG->GGG R248G	−	−	−

Differences between these results and the published data are indicated in bold. These results were compared to previously published data for WRO (Namba et al., 2003; Xu et al., 2003; Garcia-Rostan et al., 2005; Palona et al., 2006; Schweppe et al., 2008), FTC133 (Ricarte-Filho et al., 2009), B-CPAP (Garcia-Rostan et al., 2005; Meireles et al., 2007; Ricarte-Filho et al., 2009), TPC1 (Meireles et al., 2007; Ricarte-Filho et al., 2009), K1 (Garcia-Rostan et al., 2005; Meireles et al., 2007; Ricarte-Filho et al., 2009) and 8505c (Garcia-Rostan et al., 2005; Meireles et al., 2007; Ricarte-Filho et al., 2009; Nucera et al., 2010) cell lines.

^*, heterozygous mutation; wt, wild-type genotype (no mutation); +, presence of the gene rearrangement; −, absence of the gene rearrangement.